

PIN1 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP8959c

Specification

PIN1 Antibody (Center) Blocking Peptide - Product Information

Primary Accession <u>Q13526</u>

PIN1 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 5300

Other Names

Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, Peptidyl-prolyl cis-trans isomerase Pin1, PPlase Pin1, Rotamase Pin1, PIN1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP8959c was selected from the Center region of human PIN1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PIN1 Antibody (Center) Blocking Peptide - Protein Information

Name PIN1

PIN1 Antibody (Center) Blocking Peptide - Background

PIN1 is an essential nuclear peptidylprolyl cis-trans isomerase (PPlase; EC 5.2.1.8) involved in regulation of mitosis.

PIN1 Antibody (Center) Blocking Peptide - References

Lu,K.P., et.al., Nature 380 (6574), 544-547 (1996)Campbell,H.D., et.al., Genomics 44 (2), 157-162 (1997)



Function

Peptidyl-prolyl cis/trans isomerase (PPlase) that binds to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs (PubMed:21497122, PubMed:23623683, PubMed: tations/29686383" target=" blank">29686383). By inducing conformational changes in a subset of phosphorylated proteins, acts as a molecular switch in multiple cellular processes (PubMed:21497122, PubMed:22033920, PubMed:23623683). Displays a preference for acidic residues located N-terminally to the proline bond to be isomerized. Regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Down-regulates kinase activity of BTK (PubMed:16644721). Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation (PubMed:15664191). Binds and targets PML and BCL6 for degradation in a phosphorylation-dependent manner (PubMed:17828269). Acts as a regulator of JNK cascade by binding to phosphorylated FBXW7, disrupting FBXW7 dimerization and promoting FBXW7 autoubiguitination and degradation: degradation of FBXW7 leads to subsequent stabilization of JUN (PubMed: 22608923). May facilitate the ubiquitination and proteasomal degradation of RBBP8/CtIP through CUL3/KLHL15 E3 ubiquitin-protein



ligase complex, hence favors DNA double-strand repair through error-prone non-homologous end joining (NHEI) over error-free, RBBP8-mediated homologous recombination (HR) (PubMed:23623683, PubMed:27561354). Upon IL33-induced lung inflammation, catalyzes cis-trans isomerization of phosphorylated IRAK3/IRAK-M, inducing IRAK3 stabilization, nuclear translocation and expression of pro-inflammatory genes in dendritic cells (PubMed:29686383).

Cellular Location

Nucleus. Nucleus speckle. Cytoplasm Note=Colocalizes with NEK6 in the nucleus (PubMed:16476580). Mainly localized in the nucleus but phosphorylation at Ser-71 by DAPK1 results in inhibition of its nuclear localization (PubMed:21497122)

Tissue Location

Expressed in immune cells in the lung (at protein level) (PubMed:29686383). The phosphorylated form at Ser-71 is expressed in normal breast tissue cells but not in breast cancer cells

PIN1 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides